Feng Liu1, Huaiwei Zhang2, Zhou Sun2, Xiangdi Meng2, Zhaosen Ma2, Zhixin Wang2. 1. Department of Nephrology, China-Japan Union Hospital of Jilin University 126 Xiantai Street, Changchun 130031, Jilin, China. 2. Department of Urology, China-Japan Union Hospital of Jilin University 126 Xiantai Street, Changchun 130031, Jilin, China.
Abstract
OBJECTIVE: To determine the influences of etoposide combined with cisplatin on prognosis of patients with castration-resistant prostate cancer (CRPC) who failed castration treatment. METHODS: A total of 100 patients with metastatic CRPC who failed castration treatment in our hospital from January 2015 to January 2017 were retrospectively analyzed. The patients were divided into a control group (n=59) treated with docetaxel combined with prednisone and an experimental group (n=41) treated with etoposide combined with cisplatin (EP). The change in prostate-specific antigen (PSA) level was adopted as the evaluation criterion for efficacy, by which the total clinical effective rate of patients was calculated. The neurologic rating scale (NRS) was adopted to evaluate the pain of patients, and the incidence of adverse reactions was compared between the two groups. Cox regression was carried out to analyze independent prognostic factors impacting 3-year survival. RESULTS: The experimental group showed a significantly better clinical improvement than the control group (P<0.05). According to further analysis, the experimental group had a significantly higher clinical efficacy rate than the control group (P<0.05). Life quality scores of the experimental group were higher than those of the control group (all P<0.05). The two groups were not greatly different in bone pain, or incidence of adverse reactions (both P>0.05). The median survival time of the control group was 15.9 months, while that of the experimental group was 18 months, and the control group experienced a greatly shorter median survival time than the experimental group (P=0.040). According to Cox regression analysis, Gleason score, clinical stage, and metastasis were independent factors impacting the patients' 3-year prognosis (all P<0.05). CONCLUSION: EP regimen can strongly improve the 3-year survival rate of patients, without increasing adverse reactions. AJTR
OBJECTIVE: To determine the influences of etoposide combined with cisplatin on prognosis of patients with castration-resistant prostate cancer (CRPC) who failed castration treatment. METHODS: A total of 100 patients with metastatic CRPC who failed castration treatment in our hospital from January 2015 to January 2017 were retrospectively analyzed. The patients were divided into a control group (n=59) treated with docetaxel combined with prednisone and an experimental group (n=41) treated with etoposide combined with cisplatin (EP). The change in prostate-specific antigen (PSA) level was adopted as the evaluation criterion for efficacy, by which the total clinical effective rate of patients was calculated. The neurologic rating scale (NRS) was adopted to evaluate the pain of patients, and the incidence of adverse reactions was compared between the two groups. Cox regression was carried out to analyze independent prognostic factors impacting 3-year survival. RESULTS: The experimental group showed a significantly better clinical improvement than the control group (P<0.05). According to further analysis, the experimental group had a significantly higher clinical efficacy rate than the control group (P<0.05). Life quality scores of the experimental group were higher than those of the control group (all P<0.05). The two groups were not greatly different in bone pain, or incidence of adverse reactions (both P>0.05). The median survival time of the control group was 15.9 months, while that of the experimental group was 18 months, and the control group experienced a greatly shorter median survival time than the experimental group (P=0.040). According to Cox regression analysis, Gleason score, clinical stage, and metastasis were independent factors impacting the patients' 3-year prognosis (all P<0.05). CONCLUSION: EP regimen can strongly improve the 3-year survival rate of patients, without increasing adverse reactions. AJTR
Authors: Jessica C Hassel; Lucie Heinzerling; Jens Aberle; Oliver Bähr; Thomas K Eigentler; Marc-Oliver Grimm; Victor Grünwald; Jan Leipe; Niels Reinmuth; Julia K Tietze; Jörg Trojan; Lisa Zimmer; Ralf Gutzmer Journal: Cancer Treat Rev Date: 2017-05-18 Impact factor: 12.111
Authors: Ilaria Guccini; Ajinkya Revandkar; Mariantonietta D'Ambrosio; Manuel Colucci; Emiliano Pasquini; Simone Mosole; Martina Troiani; Daniela Brina; Raheleh Sheibani-Tezerji; Angela Rita Elia; Andrea Rinaldi; Nicolò Pernigoni; Jan Hendrik Rüschoff; Susanne Dettwiler; Angelo M De Marzo; Emmanuel S Antonarakis; Costanza Borrelli; Andreas E Moor; Ramon Garcia-Escudero; Abdullah Alajati; Giuseppe Attanasio; Marco Losa; Holger Moch; Peter Wild; Gerda Egger; Andrea Alimonti Journal: Cancer Cell Date: 2020-11-12 Impact factor: 31.743
Authors: Joaquin Mateo; Karim Fizazi; Silke Gillessen; Axel Heidenreich; Raquel Perez-Lopez; Wim J G Oyen; Neal Shore; Matthew Smith; Christopher Sweeney; Bertrand Tombal; Scott A Tomlins; Johann S de Bono Journal: Eur Urol Date: 2018-08-14 Impact factor: 20.096